Risk factors for malignancy in Japanese renal transplant recipients

Cancer

Volumn 109, Issue 10, 2007, Pages 2109-2115

  Imao, Tetsuya ^a   Ichimaru, Naotsugu ^a   Takahara, Shiro ^a   Kokado, Yukito ^a   Okumi, Masayoshi ^a   Imamura, Ryoichi ^a   Namba, Yukiomi ^a   Isaka, Yoshitaka ^a   Nonomura, Norio ^a   Okuyama, Akihiko ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Immunosuppressant; Malignancy; Renal transplantation; Risk factor

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; ASIAN; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY TRANSPLANTATION; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SIDE EFFECT; SURVIVAL RATE;

ADULT; AGE FACTORS; AZATHIOPRINE; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPAN; KIDNEY TRANSPLANTATION; MALE; NEOPLASMS; RISK FACTORS; SURVIVAL RATE; TACROLIMUS;

EID: 34248377240     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22636     Document Type: Article

References (23)

1. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004;4:378-383.
2. Soulillou JP, Giral M. Controlling the incidence of infection and malignancy by modifying immunosuppression. Transplantation. 2001;72(12 Suppl):S89-93.
3. Stel VS, van Dijk PC, van Manen JG, et al. Prevalence of co-morbidity in different European RRT populations and its effect on access to renal transplantation. Nephrol Dial Transplant. 2005;20:2803-2811.
4. London NJ, Farmery SM, Will EJ, Davison AM, Lodge JP. Risk of neoplasia in renal transplant patients. Lancet. 1995;346:403-406.
5. Penn I. Malignancies associated with immunosuppressive or cytotoxic therapy. Surgery. 1978;83:492-502.
6. Birkeland SA, Storm HH, Lamm LU, et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer. 1995;60:183-189.
7. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4:905-913.
8. Hoshida Y, Tsukuma H, Yasunaga Y, et al. Cancer risk after renal transplantation in Japan. Int J Cancer. 1997;71:517-520.
9. Marcen R, Pascual J, Tato AM, et al. Influence of immunosuppression on the prevalence of cancer after kidney transplantation. Transplant Proc. 2003;35:1714-1716.
10. Agraharkar ML, Cinclair RD, Kuo YF, Daller JA, Shahinian VB. Risk of malignancy with long-term immunosuppression in renal transplant recipients. Kidney Int. 2004;66:383-389
11. Opelz G, Dohler B. Lymphomas after solid organ transplantation a collaborative transplant study report. Am J Transplant. 2004;4:222-230.
12. Bustami RT, Ojo AO, Wolfe RA, et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant. 2004;4:87-93.
13. Ichimaru N, Toki K, Wang JD, et al. Malignant neoplasms after renal transplantation. Renal Transplant Vasc Surg. 1999;11:3-6.
14. Tang S, Lui SL, Li FK, Lo WK, Chan TM, Lai KN. Long-term renal allograft recipients from South-east Asia in the precyclosporin era. Int J Artific Organs. 1999;22:131-137.
15. The Japanese Society for Clinical Renal Transplantation. The Japanese Society for Transplantation Annual progress report from the Japanese Renal Transplant Registry, 2003, Part III. Results from 2000 follow-up survey. Ishoku. 2004;39:57-64.
16. Maisonneuve P, Agodoa L, Gellert R, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet. 1999;354:93-99.
17. Penn I. The changing pattern of posttransplant malignancies. Transplant Proc. 1991;23(1 Pt 2):1101-1103.
18. Hoshida Y, Aozasa K. Malignancies in organ transplant recipients. Pathol Int. 2004;54:649-658.
19. Kahan BD, Yakupoglu YK, Schoenberg L, et al. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation. 2005;80:749-758.
20. Landewe RB, van den Borne BE, Breedveld FC, Dijkmans BA. Does cyclosporin A cause cancer? Nat Med. 1999;5:714.
21. Jensik SC. Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial.FK 506 Kidney Transplant Study Group. Transplant Proc. 1998;30:1216-1218.
22. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients meta-analysis and meta-regression of randomized trial data. BMJ. 2005;331:810-820.
23. Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation. 2005;80:1233-1243.